Sessions for 2009


Symposium I - Prescription Opioid Use and Addiction
Elinore McCance-Katz, MD, PhD, Symposium Chair
Presenters: Art Van Zee, MD; Jon Streltzer, MD; and Penelope Ziegler, MD
This symposium will explore what steps are being taken to curb the current epidemic, identify effective alternative treatments for chronic pain, demonstrate how to safely use opioids when clinically indicated for patients with chronic non-cancer pain, how to screen pain patients for risk of addiction, and how to detect misuse and addiction.
Sponsored by the Center for Substance Abuse Treatment , Substance Abuse and Mental Health Services Administration

Symposium II - Illicit Drug Use Disorders in the United States: Results from NESARC
Wilson M. Compton, MD, MPE and Howard Moss, MD, Symposium Co-Chairs
Presenters:  Carlos Blanco, MD; Deborah Hasin, PhD; and Sean Esteban McCabe, PhD
Taking advantage of data from both the baseline with over 43,000 subjects and the three year follow-up with over 34,000 persons, NESARC provides a rich source of information about a broad range of addictive and psychiatric disorders in the U.S. household population.  This symposium is expected to address the topic of illicit drug use disorders including information on:  1) co-occurring mental and illicit drug use disorders (Blanco), 2) personality disorders and the course of drug use disorders (Hasin), and 3) sexual orientation and drug use disorders (McCabe).
Sponsored by the National Institute on Drug Abuse

Symposium III - Treatment of Co-occurring Substance Use and Attention Deficit Hyperactivity Disorder: New Findings from the NIDA Clinical Trials Network
Edward Nunes, MD, Symposium Chair
Presenters: Theresa Winhusen, PhD; Paula Riggs, MD; and Frances Levin, MD
This symposium will present the main findings from two multi-site trials of long-acting methylphenidate among substance dependent patients, conducted in the NIDA Clinical Trials Network.
Sponsored by the National Institute on Drug Abuse

Symposium IV - Personalized Medicine for Addiction Psychiatry: How Close Are We?
Mark L. Willenbring, MD, Symposium Chair
Presenters:  Howard Moss, MD;  Katie Witkiewitz, PhD; and David Oslin, MD
This NIAAA symposium will explore current findings and future directions related to the ability to predict treatment response through the use of specific tests or other clinically accessible information. Including fields such as genetics, genomics, cognitive neuroscience, imaging and pharmacology, speakers will focus on areas where clinical application is either available now or is likely to be in the near future.
Sponsored by the National Institute on Alcohol Abuse and Alcoholism

Workshop Topics

Click on the links below for workshop descriptions (PDF):

Concurrent Workshop Session A: Friday, December 4, 2009  ~  11:00 am - 12:30 pm

Concurrent Workshop Session B: Friday, December 4, 2009  ~  1:45 pm - 3:15 pm

Concurrent Workshop Session C: Saturday, December 5, 2009  ~  1:30 pm - 3:00 pm

2009 Workshop Titles:

Workshop Session A

  • Workshop A1: Beyond Licensing: Getting Psychiatry Residents Excited About Prescribing Buprenorphine
  • Workshop A-2: Transitional Aged Youth with Addiction: The New Frontier
  • Workshop A-3: Methamphetamine and HIV Treatment
  • Workshop A4: Addiction in Film 7: The Demise and Rise of a "Jackass"
  • Workshop A-5: Methamphetamine Use Disorders: Associated Symptoms and Treatment Options

Workshop Session B

  • Workshop B1: Mindfulness for Co-Occurring Disorders
  • Workshop B2: Buprenorphine 201
  • Workshop B3: Facilitating Twelve-Step Participation: An In-Vivo Demonstration
  • Workshop B4: Nonchemical Addictions: New Classification, Psychopathology and Therapeutic Strategies
  • Workshop B5: The Impact of Marijuana on Mental Health

Workshop Session C

  • Workshop C1: Brain, Body and Spirit Enhancing Medications
  • Workshop C2: Extended-Release Naltrexone (XR-NTX) in General Medical and Psychiatric Settings
  • Workshop C3: The Woodstock Generation: Substance Abuse Assessment and Evidence Based Treatment in the Aging Baby Boomer
  • Workshop C4: Treating Patients who are Abusing Sedative-Hypnotic Agents
  • Workshop C5: Leadership and Administration in Addiction Psychiatry

Case Conference

Michael M. Scimeca, MD, Chair, Moderator
Fellow: Margaret M. Benningfield, MD

Clinicians: Elizabeth F. Howell, MD, DFAPA, FASAM and Joseph G. Liberto, MD

The case conference provides an opportunity to learn, teach and share clinical experiences.  A Fellow briefly presents a problematic treatment case. Two noted senior clinicians discuss the case presenting their personal clinical approaches:  sharing their therapeutic styles and thinking.  This approach focuses on stimulating the audience to actively participate with their own case vignettes, opinions, reactions and provocative questions.  This year the case will focus on the difficulties of an addicted woman with motherhood.

View Case Conference presentation here.

Medical Update

Medical Update: Managing Pain in the Addicted Patient
Presenter: Karen A. Miotto, MD

Clinicians need to evaluate, manage or co-manage pain in patients who are in different stages of addiction including active, in recovery, or on agonist therapy.  Educational objectives are to help physicians and other health care professionals:

  • Better utilize the tools and techniques of addiction safeguards and settings for patients who are currently in addiction treatment or in recovery
  • Determine optimum pain treatment or treatment safeguards and settings for patients who are currently in addiction treatment or in recovery
  • Identify the concerns about withdrawal mediated pain, opioid tolerance and hyperalgesia in pain management
  • Review current and developing strategies for pain management in methadone and buprenorphine maintained patients
  • Take appropriate steps to monitor for effectiveness of the pain medications and to minimize the potential for diversion, abuse, or addiction